The U.S. Food and Drug Administration recently announced that all doses of Eli Lilly’s highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the United States. This update comes as a relief to many individuals who have been struggling to access these medications due to previous shortages. It was reported that some doses of Mounjaro had been in short supply since as early as 2022, while doses of Zepbound were added to the FDA’s shortage list earlier this year following its U.S. approval in November.
The high demand for weight loss and diabetes drugs has been an ongoing issue, with supply struggling to meet the needs of patients. Both Eli Lilly and its rival Novo Nordisk have had to invest billions in ramping up manufacturing in order to address this demand. The shortages of Mounjaro and Zepbound have been a cause of concern for many, but according to Eli Lilly CEO David Ricks, these shortages are expected to end very soon. In an interview with Bloomberg, Ricks mentioned that they plan to exit the shortage process within the next few days, providing hope for individuals relying on these medications.
In addition to Eli Lilly’s drugs, the FDA also reported that all doses of Novo Nordisk’s diabetes injection Ozempic are now available in the U.S. This is another positive development for individuals managing diabetes. However, the FDA noted that some doses of Novo Nordisk’s weight loss drug Wegovy still have limited supply, indicating that there are ongoing challenges in meeting the demand for these medications.
Overall, the availability of these popular drugs in the U.S. is a positive step forward in ensuring that individuals have access to the treatments they need to manage their health conditions. The efforts made by both Eli Lilly and Novo Nordisk to address the supply shortages demonstrate their commitment to supporting patients and providing essential medications. With these updates, patients can look forward to easier access to these vital drugs.